HLS Therapeutics (HLS) Investor presentation summary

Business profile and outlook

• North American specialty pharma model focused on acquiring US and Canadian commercialization rights across cardiovascular and neuro/psychiatric products.

• 2025 revenue was US$55.5M and adjusted EBITDA was US$19.6M; 2026 guidance is US$56–60M revenue and US$18.5–21M adjusted EBITDA.

• Portfolio spans Vascepa, Nilemdo and Nexlizet in cardiovascular care, plus Clozaril and related support and monitoring services in neuro/psychiatry.

Cardiovascular portfolio and catalysts

• Vascepa YTD 2026 units rose 17% and net sales rose 16% vs YTD 2025; patent protection extends through the late 2030s, with expanding operating margin.

• Nilemdo, launched in March 2026, is positioned for LDL-C lowering and cardiovascular event prevention; ~80% of eligible privately insured patients had reimbursement coverage.

• Public reimbursement listings for Nilemdo are expected in H1 2027 following a unanimous Canadian Drug Agency reimbursement recommendation.

• Nexlizet combines bempedoic acid and ezetimibe, with ~38% LDL-C reduction in US and European indications; Health Canada decision targeted by year-end 2026 and launch planned for H1 2027, subject to approval.

• Illustrative Nilemdo/Nexlizet opportunity estimates C$50–100M revenue at 10–20% market penetration, based on net pricing and patient compliance assumptions.

Clozaril and psychiatric services

• Clozaril contributed US$27M in brand contribution in 2025; branded share is ~50% of Canada’s clozapine market, and the presentation describes cash flow as stable.

• Clozaril Support & Assistance Network offers nurse educators, clinical coordinators and physician consultants; reported compliance was 32% higher vs the leading generic.

• CSAN Pronto provides point-of-care white blood cell testing, while MyCare Psychiatry generates revenue through therapeutic drug monitoring.